A5004315411- RNA modifications and cancer
- Gastrointestinal Tumor Research and Treatment
- Vascular Malformations and Hemangiomas
- RNA Research and Splicing
- Cancer-related gene regulation
- Sarcoma Diagnosis and Treatment
- Cancer-related molecular mechanisms research
- Platelet Disorders and Treatments
- Neurofibromatosis and Schwannoma Cases
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Viral-associated cancers and disorders
Fudan University Shanghai Cancer Center
2024
Nanjing Medical University
2022-2023
Jiangsu Province Hospital
2022-2023
Jiangsu Cancer Hospital
2022
Background: Long non-coding RNAs modulate tumor occurrence through different molecular mechanisms. It had been reported that HNF1A-AS1 (HNF1A Antisense RNA 1) was differently expressed in multiple tumors. The role of colorectal cancer less analyzed, and the mechanism regulating cell cycle has not completely elucidated. Methods: Differentially lncRNAs were screened out from TCGA database. examined CRC clinical samples lines by RT-qPCR. CCK8 assay, colony formation flow cytometry, transwell...
N6-methyladenosine (m6A) is a frequently occurring mRNA modification, which regulates stability, splicing, and translation. However, its role in drug resistance of gastrointestinal stromal tumor (GIST) not known. Here, we report that m6A modification levels are elevated imatinib-resistant GIST cells tissues, methyltransferase METTL3 one the main protein responsible for this aberrant modification. Increased contributed to imatinib worse progression-free survival patients. Mechanistic studies...
Ripretinib, a broad-spectrum inhibitor of the KIT and PDGFRA receptor tyrosine kinases, is designated as fourth-line treatment for gastrointestinal stromal tumor (GIST). It tailored patients resistant to imatinib, sunitinib, regorafenib. As its increasing use, instances resistance ripretinib are becoming more frequent. Unfortunately, there currently no scientifically mature options available ripretinib. Posttranslational modifications (PTMs) such ubiquitination, in conjunction with interplay...